| | 一、药品基本情况 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 序 号 | 产品 名称 | 药品生 产企业 | 剂型 | 规格 | 药品 | 注册 | 药品注册 | 通知书编号 | 药品 批准文号 | 适用症 | | | | | | | 批准文号 | 分类 | 标准编号 | | 有效期 | 活血化瘀，理气止痛。用于 | | 1 | 复方 | 黄山 | 片剂 | 每片重 | 国药准字 | 中药 | 《中国药典》 | 2025R050976 | 至 2030 年 | 气滞血瘀所致的胸痹，症见 | | | 丹参片 | 天目 | | 0.25g | Z34020312 | | 2020 版一部 | | 06 月 05 日 | 胸闷、心前区刺痛；冠心病 | | | | | | | | | | | | 心绞痛见上述证候者。 | | | | | | | | | 部颁标准中药 | | | 滋养肝肾，祛风明目。用于 | | 2 | 桑麻丸 | 黄山 | 丸剂 | 每 50 粒 重约 3g ...

Performance Meeting Overview - The company held its 2024 annual performance meeting on June 5, 2025, via an online interactive format at the Shanghai Stock Exchange [1] - Key executives including the Secretary of the Board, CFO, and an independent director participated in the meeting to address investor inquiries [1] Product Registration and Development - As of now, the company has completed re-registration for 29 drug numbers at its Lin'an Pharmaceutical Center, with 11 drug numbers at Huangshan Tianmu and Huangshan Mint also completed [2] - The company is working on small-scale trials and commissioned processing for some re-registered drug numbers to enhance its product diversity [2] Key Product Updates - The company's flagship product, Pearl Eye Drops, is undergoing preparations for GMP compliance checks, but the timeline for resuming normal production and sales remains uncertain [2] - The company has launched White Flower Snake Grass Water in collaboration with East China Grape Brewing Co., achieving sales revenue of 342.32 million yuan in 2024 [2] Health Product Strategy - The company is focused on a dual strategy of "premium traditional Chinese medicine + health products," aiming to expand its health product offerings [3] - New products such as Iron Skin Fengtou tablets, soft capsules, and extracts have been added to the existing product line [3] Collaborations and Market Expansion - The company has established a subsidiary for research and development in traditional Chinese medicine and health products, collaborating with renowned TCM teams [3] - Partnerships with Qingdao University aim to innovate TCM applications in health foods and functional products [3] E-commerce Initiatives - The company launched its flagship store on Tmall in May 2025, facilitating online sales of its Iron Skin Fengtou product line [4] - The company plans to leverage internet channels to enhance product promotion and expand market share [4] Mergers and Acquisitions - The company has adopted a cautious yet open approach to mergers and acquisitions, having acquired 51% stakes in Qingdao Simulation Medical Technology Co., Ltd. and Qingdao Tianmu Mountain Medical Technology Co., Ltd. in 2024 [5] - These acquisitions are expected to improve asset quality and enhance the company's operational capabilities [5]

证券代码：600671 证券简称：天目药业 公告编号：临 2025-029 杭州天目山药业股份有限公司 关于 2024 年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 杭州天目山药业股份有限公司（以下简称"公司"或"天目药业"）于 2025 年 6 月 5 日 15:00-16:00 在上海证券交易所上证路演中心 （https://roadshow.sseinfo.com/）通过网络互动方式召开 2024 年度业绩说明 会。现就有关事项公告如下： 一、 业绩说明会召开情况 2025 年 5 月 27 日，公司在上海证券交易所网站（www.sse.com.cn）及指定 信息披露媒体披露了《杭州天目山药业股份有限公司关于召开 2024 年度业绩说 明会的公告》。 2025 年 6 月 5 日 15:00-16:00，公司董事长刘加勇先生、总经理孙学建先生、 董事会秘书党国峻先生、财务总监王一惠女士、独立董事盛筱艨女士出席了本次 业绩说明会，与投资者进行沟通与交流，就投资者关注的问题进行了回复。 二、 ...

证券代码：600671 证券简称：天目药业 公告编号：临 2025-028 杭州天目山药业股份有限公司 关于全资子公司收到药品再注册批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 杭州天目山药业股份有限公司（以下简称"公司"）获悉，公司下属全资子 公司黄山市天目药业有限公司（以下简称"黄山天目"）于近日收到安徽省药品 监督管理局核准签发的《药品再注册批准通知书》。现将相关情况公告如下： 一、药品再注册批准通知书的主要信息 1、生脉饮 通知书编号：2025R038451 剂型：合剂 申请事项：境内生产药品再注册 规格：每支装 10ml 注册分类：中药 药品注册标准编号：《中国药典》2020 版一部 原药品批准文号：国药准字 Z34020345 包装规格：10ml×10 支/盒 药品有效期：24 个月 审批结论：经审查，同意本品再注册。由于本品长期未生产，恢复生产时， 须向我局提出现场检查申请，经我局现场检查并抽验一批产品合格后，方可上市 销售。 上市许可持有人/生产企业：黄山市天目药业有限公司 药品批准文号：国 ...

证券代码：600671 证券简称：天目药业 公告编号：临 2025-027 杭州天目山药业股份有限公司 关于召开 2024 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 06 月 05 日 （星期四） 15:00-16:00 会议召开地点：上海证券交易所上证路演中心 （网址：https://roadshow.sseinfo.com/） 就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2025 年 06 月 05 日（星期四）15:00-16:00 （二） 会议召开地点：上证路演中心 （三） 会议召开方式：上证路演中心网络互动 三、 参加人员 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 05 月 28 日（星期三）至 06 月 04 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 tianmuyaoye@126.com 进行提问。公司将在说明会上对投资者普遍关注 的问 ...

截至2025年5月23日收盘，天目药业(600671)报收于12.35元，下跌0.64%，换手率4.2%，成交量5.11万 手，成交额6427.05万元。 董秘最新回复 投资者： 请问截止5月20日在册股东人数？ 董秘： 尊敬的投资者，您好！截至2025年5月20日，公司的股东人数为9075户，感谢您的关注。 投资者： 新的重组办法已经发布，很多上企业在互动交流中明确告诉投资者，会将并购做为提高上市 公司高经营质量的选项之一，请问天目山药业将来是否也会在合适时间开展并购工作，提高公司经营质 量。 董秘： 尊敬的投资者，您好！公司持续关注市场动态和政策导向，加强对证监会最新发布的《上市公 司重大资产重组管理办法》的学习，如涉及相关事项，将严格按照相关法律法规的要求，及时履行信息 披露义务。感谢您的关注。 投资者： 为何摘帽之后反而大跌。 投资者： 天目山药业深圳子公司近期注册了很多宠物行业和食品行业的商标，请问子公司是不是要进 入宠物行业和保健快销食品行业 董秘： 尊敬的投资者，您好！公司全资子公司天目山健康科技（深圳）有限公司主要从事大健康品类 业务，出于商标保护考虑，申请注册"天目山药业""天目健康""天目 ...

2024年，天目药业业绩有所好转。公司方面称，公司内部控制缺陷整改已完成，内控有效运行。公司涉 及的其他风险警示情况已经消除，且不存在退市风险警示及其他风险警示的情形。 天目药业总部位于杭州，但控股股东为国有独资企业青岛汇隆华泽投资有限公司，实际控制人为青岛市 崂山区财政局。 值得注意的是，天目药业2024年业绩好转的主要原因是：2024年下半年，天目药业的保健品和医学培训 业务获得大量来自实控人所在地——青岛相关企业或单位的"输血"。天目药业在2024年第三、第四季度 的营业收入占全年营业收入的比例分别为29.97%、42.62%，合计占比为72.59%。 2024年下半年业务获得突击输血，帮助天目药业业绩实现好转。不过，未来相关业务又能否持续？针对 相关疑问，《中国经营报》记者联系了天目药业方面，不过未得到回应。 中经记者 晏国文 卢志坤 北京报道 | | | | | | | 应收账款期末余额 | | 与公司控股股东、 实际控制人及其关 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 结算 | | | | | | 序号 ...

Core Viewpoint - Hangzhou Tianmu Mountain Pharmaceutical Co., Ltd. (Tianmu Pharmaceutical) has successfully ended its "ST" status after being delisted from risk warnings by the Shanghai Stock Exchange, marking a significant turnaround in its performance following the acquisition by Qingdao Laoshang State-owned Assets [1][3] Company Overview - Tianmu Pharmaceutical, established in 1958 and listed in 1993, has faced numerous challenges over its 30-year history, including governance issues and financial losses, leading to its stock being under risk warnings since June 2020 [2][3] - The company was acquired by Qingdao Huilong Huaze Investment Co., Ltd. in August 2023, which became the new controlling shareholder, providing a much-needed capital infusion of over 1.1 billion yuan for a 29.99% stake [3][4] Financial Performance - Following the acquisition, Tianmu Pharmaceutical's revenue is projected to grow by 78.44% to 217 million yuan in 2024, with a net profit turnaround to 15.25 million yuan [4] - In the first quarter of the current year, the company reported an 88.55% increase in revenue, surpassing 5 million yuan in net profit [4] Strategic Initiatives - The new management has implemented several measures, including waiving 90 million yuan in debt and providing over 100 million yuan in bank credit guarantees, which have positively impacted the company's operations [4] - Tianmu Pharmaceutical is pursuing a dual-center strategy, consolidating its traditional business in Hangzhou while establishing a northern sales center in Qingdao to expand into the Shandong and North China markets [4] Industry Context - The revitalization of Tianmu Pharmaceutical is seen as beneficial for the pharmaceutical and health industry in Laoshang District, which aims to leverage the company's brand to stimulate broader industry growth [5] - The company is actively exploring new avenues in the health industry, transitioning towards a "Chinese medicine + health" model and aiming for an integrated approach in research, production, and sales [5]

6只ST/*ST股将"摘星脱帽"。 Wind统计数据显示，根据上市公司公告，截至发稿，明日（5月20日）将有8只A股复牌。 其中，ST中泰、ST升达等6股均因撤销退市风险警示、其他风险警示而在今日（5月19日）停牌一天， 将自明日复牌，股票代码不变，股票简称均有所变化。 慧博云通和信邦智能则是发布了重大资产重组预案，并宣布复牌。 6股即将"摘星脱帽" 20日复牌 *ST傲农（603363）此前公告，公司股票将自5月20日撤销退市风险警示及其他风险警示并复牌，股票 简称由"*ST傲农"变更为"傲农生物"，股票代码不变。 根据公告，2025年4月28日，容诚会计师事务所（特殊普通合伙）对公司2024年度财务报告出具了标准 无保留意见的审计报告。经审计，截至2024年12月31日，公司期末归属于上市公司股东的净资产为 25.66亿元；2024年度，公司实现营业收入87.63亿元，实现归属于上市公司股东的净利润为5.79亿元。 此外，根据公司《董事会关于2023年度审计报告非标意见涉及事项影响已消除的专项说明》，董事会认 为，公司2023年度审计报告非标意见涉及事项的影响已消除。容诚会计师事务所（特殊普通合伙）于 2 ...

Core Viewpoint - ST Muyu Pharmaceutical Co., Ltd. is undergoing a strategic transformation following a change in control, with improved financial performance and operational efficiency expected in the coming years [2][3]. Group 1: Company Overview - ST Muyu is the first A-share listed company in Hangzhou and the first A-share listed company for traditional Chinese medicine preparations in China [2]. - The actual controller of the company has changed to the Qingdao Laoshan District Finance Bureau, which has led to a series of equity acquisitions and management changes [2]. Group 2: Financial Performance - In 2024, the company achieved a net profit attributable to shareholders of 15.25 million yuan, with a net profit of 9.96 million yuan after deducting non-recurring gains and losses [2]. - The company reported a significant increase in revenue for the first quarter of 2025, reaching 52.29 million yuan, representing a year-on-year growth of 88.55% [3]. - The net profit for the first quarter of 2025 was 5.09 million yuan, marking a turnaround from previous losses [3]. Group 3: Management and Strategy - A professional management team with rich industry experience has been established under the new state-owned control, which is expected to enhance decision-making and market positioning [3]. - The company is focusing on core businesses such as traditional Chinese medicine, raw materials, and health products, while also optimizing operational strategies to reduce costs and increase efficiency [3]. - The completion of internal control defect rectification has been confirmed, with a standard unqualified opinion issued by the accounting firm on the internal control audit report [3].